Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Taxes (2016 - 2018)

Historic Current Taxes for Enanta Pharmaceuticals (ENTA) over the last 5 years, with Q4 2018 value amounting to $5.9 million.

  • Enanta Pharmaceuticals' Current Taxes fell 4288.78% to $5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $5.9 million, marking a year-over-year decrease of 4288.78%. This contributed to the annual value of $1.4 million for FY2018, which is 8507.21% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Current Taxes stood at $5.9 million for Q4 2018, which was down 4288.78% from $1.4 million recorded in Q3 2018.
  • In the past 5 years, Enanta Pharmaceuticals' Current Taxes registered a high of $16.9 million during Q4 2014, and its lowest value of $1.2 million during Q3 2015.
  • For the 5-year period, Enanta Pharmaceuticals' Current Taxes averaged around $6.8 million, with its median value being $5.6 million (2018).
  • Its Current Taxes has fluctuated over the past 5 years, first skyrocketed by 3198.74% in 2016, then tumbled by 8507.21% in 2018.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Current Taxes stood at $16.9 million in 2014, then crashed by 70.76% to $4.9 million in 2015, then tumbled by 40.45% to $2.9 million in 2016, then surged by 248.64% to $10.3 million in 2017, then crashed by 42.89% to $5.9 million in 2018.
  • Its last three reported values are $5.9 million in Q4 2018, $1.4 million for Q3 2018, and $5.4 million during Q1 2018.